Trading Report: Today, Sonata Capital Group Inc. invests in Bristol-Myers Squibb Co. (BMY) Shares

Today, Sonata Capital Group Inc. invests in Bristol-Myers Squibb Co. (BMY) Shares

Sonata Capital Group Inc. raised its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 80.8% during the third quarter, Holdings Channel reports. The firm owned 5,035 shares of the biopharmaceutical company’s stock after buying an additional 2,250 shares during the period. Sonata Capital Group Inc.’s holdings in Bristol-Myers Squibb were worth $271,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in BMY. Vanguard Group Inc. boosted its position in shares of Bristol-Myers Squibb by 3.4% in the second quarter. Vanguard Group Inc. now owns 109,554,831 shares of the biopharmaceutical company’s stock valued at $8,057,758,000 after buying an additional 3,595,648 shares during the period. Bank of Montreal Can bought a new stake in shares of Bristol-Myers Squibb during the second quarter valued at $154,732,000. Sustainable Growth Advisers LP raised its stake in shares of Bristol-Myers Squibb by 1,957.1% in the second quarter. Sustainable Growth Advisers LP now owns 1,402,482 shares of the biopharmaceutical company’s stock valued at $103,153,000 after buying an additional 1,334,303 shares in the last quarter. Jarislowsky Fraser Ltd raised its stake in shares of Bristol-Myers Squibb by 240.6% in the second quarter. Jarislowsky Fraser Ltd now owns 1,885,751 shares of the biopharmaceutical company’s stock valued at $100,571,000 after buying an additional 1,332,163 shares in the last quarter. Finally, WestEnd Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the second quarter valued at $94,956,000. Hedge funds and other institutional investors own 71.28% of the company’s stock.

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded up 0.41% during midday trading on Friday, reaching $56.98. The company’s stock had a trading volume of 6,228,571 shares. Bristol-Myers Squibb Co. has a 12 month low of $49.03 and a 12 month high of $77.12. The stock has a 50-day moving average of $52.69 and a 200 day moving average of $63.10. The company has a market cap of $95.23 billion, a price-to-earnings ratio of 28.50 and a beta of 0.90.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.12. Bristol-Myers Squibb had a return on equity of 28.98% and a net margin of 18.54%. The firm earned $4.83 billion during the quarter, compared to the consensus estimate of $4.76 billion. During the same quarter in the previous year, the company posted $0.39 EPS. The business’s revenue for the quarter was up 21.0% compared to the same quarter last year. On average, analysts predict that Bristol-Myers Squibb Co. will post $2.85 earnings per share for the current fiscal year.

Several equities research analysts have weighed in on the company. SunTrust Banks Inc. lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $86.00 to $68.00 in a research report on Friday, August 5th. Zacks Investment Research lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. Citigroup Inc. dropped their target price on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating on the stock in a research report on Wednesday, August 3rd. Leerink Swann reaffirmed a “buy” rating and issued a $85.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, July 29th. Finally, Piper Jaffray Cos. reaffirmed a “neutral” rating and issued a $65.00 target price (down from $69.00) on shares of Bristol-Myers Squibb in a research report on Monday, August 8th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $67.51.

In other news, Director Lamberto Andreotti sold 21,600 shares of the business’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $56.87, for a total transaction of $1,228,392.00. Following the completion of the sale, the director now owns 334,499 shares in the company, valued at $19,022,958.13. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 0.24% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Related posts

Leave a Comment